Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren's syndrome

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2434-2440

  Downie Doyle, Sarah ^a   Bayat, Noushin ^b,c   Rischmueller, Maureen ^b   Lester, Susan ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SJOEGREN SYNDROME; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; DISORDERS OF EXCESSIVE SOMNOLENCE; DNA FINGERPRINTING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RESTRICTION MAPPING; SJOGREN'S SYNDROME; UROLOGIC DISEASES;

EID: 33746945480     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22004     Document Type: Article

References (31)

1. Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, et al. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003;171:5673-7.
2. Brunner-Weinzierl MC, Hoff H, Burmester GR. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004;6:45-54.
3. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.
4. Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 2003;64:936-40.
5. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 2004;12:620-6.
6. Milicic A, Brown MA, Wordsworth BP. Polymorphism in codon 17 of the CTLA-4 gene (+49 A/G) is not associated with susceptibility to rheumatoid arthritis in British Caucasians. Tissue Antigens 2001;58:50-4.
7. Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, et al. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet 2005;13:823-8.
8. Bolstad AI, Jonsson R. Genetic aspects of Sjogren's syndrome. Arthritis Res 2002;4:353-9.
9. Rischmueller M, Lester S, Chen Z, Champion G, Van Den Berg R, Beer R, et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS). Clin Exp Immunol 1998;111:365-71.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K, et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren's syndrome. J Rheumatol 2003;30:2406-12.
12. Torres B, Aguilar F, Franco E, Sanchez E, Sanchez-Roman J, Jimenez Alonso J, et al. Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis Rheum 2004;50:2211-5.
13. Amundsen SS, Naluai AT, Ascher H, Ek J, Gudjonsdottir AH, Wahlstrom J, et al. Genetic analysis of the CD28/CTLA4/ICOS (CELIAC3) region in coeliac disease. Tissue Antigens 2004;64:593-9.
14. Munthe-Kaas MC, Carlsen KH, Helms PJ, Gerritsen J, Whyte M, Feijen M, et al. CTLA-4 polymorphisms in allergy and asthma and the TH1/TH2 paradigm. J Allergy Clin Immunol 2004;114:280-7.
15. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
16. King AL, Moodie SJ, Fraser JS, Curtis D, Reid E, Dearlove AM, et al. Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur J Immunogenet 2003;30:427-32.
17. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004;50:882-91.
18. Roblin X, Helluwaert F, Bonaz B. Celiac disease must be evaluated in patients with Sjogren syndrome [letter]. Arch Intern Med 2004;164:2387.
19. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46: 741-7.
20. Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004;76:14-8.
21. Kuiper HM, Brouwer M, Linsley PS, van Lier RA. Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 1995;155:1776-83.
22. Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW, et al. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 2005;52:1148-59.
23. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005;11:85-9.
24. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002; 277:46478-86.
25. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
26. Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, et al. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2005;2:8.
27. Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:673-81.
28. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-94.
29. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M. IL-1 gene family haplotypes and Raynaud's phenomenon in primary Sjogren's syndrome [letter]. Rheumatology (Oxford) 2002; 41:206-8.
30. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000;43: 1647-54.
31. Lashley FR. A review of sleep in selected immune and autoimmune disorders. Holist Nurs Pract 2003;17:65-80.